July 29, 2026 Amgen Inc. Receives Positive CHMP Opinion for Expanded Use of Repatha® Amgen's Repatha® has received a positive opinion from the CHMP for expanded use in adults at high risk for cardiovascular disease. Based on the VESALIUS-CV trial results, Repatha significantly lowers LDL cholesterol and reduces major adverse cardiovascular events, potentially transforming care for high-risk patients in Europe.
July 28, 2026 Amgen Inc. Set to Reveal Q2 2026 Financial Results Amgen Inc. is set to report its Q2 2026 financial results on August 4, with a conference call led by CEO Robert A. Bradway. The call will provide insights into the company's performance and future strategies, and will be accessible via webcast for public engagement.
June 07, 2026 Amgen's Groundbreaking Data Presentation at the ADA 86th Scientific Sessions Amgen presented groundbreaking data at the ADA 2026, highlighting the VESALIUS-CV trial results for Repatha, which significantly reduced cardiovascular events in high-risk diabetes patients. The company also addressed treatment adherence challenges and reaffirmed its commitment to cardiometabolic health.
June 04, 2026 Amgen Set to Present at Goldman Sachs 47th Annual Global Healthcare Conference Amgen Inc. will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, featuring insights from key executives. The event will be available via live webcast, ensuring accessibility for all stakeholders.
June 03, 2026 Amgen Unveils Promising Data at EULAR 2026 Congress Amgen presented groundbreaking data at EULAR 2026, showcasing the efficacy of UPLIZNA for IgG4-related disease and real-world evidence for TAVNEOS in ANCA-associated vasculitis. These findings emphasize the need for innovative treatments in rare autoimmune conditions.
June 01, 2026 Amgen Inc. Secures European Approval for IMDYLLTRA® to Treat Extensive-Stage Small Cell Lung Cancer Amgen has secured European Commission approval for IMDYLLTRA® (tarlatamab) as a treatment for extensive-stage small cell lung cancer, demonstrating significant survival benefits over traditional chemotherapy. This milestone reflects Amgen's commitment to innovative oncology solutions and offers new hope for patients facing limited treatment options.
May 29, 2026 Amgen Inc. to Showcase Innovations at Jefferies Global Healthcare Conference Amgen Inc. will showcase its latest innovations at the Jefferies Global Healthcare Conference on June 4, 2026. Key executives will present via a live webcast, emphasizing the company's commitment to transparency and innovation in biotechnology.
May 19, 2026 Amgen Inc. Announces Retirement of CFO Peter Griffith and Welcomes Thomas Dittrich Amgen Inc. announces the retirement of CFO Peter Griffith and the return of Thomas Dittrich as his successor. Griffith's leadership has fortified Amgen's financial foundation, while Dittrich's extensive experience positions the company for future growth and innovation.
May 07, 2026 Amgen Set to Present at Bank of America Merrill Lynch Global Healthcare Conference Amgen Inc. is set to participate in the Bank of America Merrill Lynch Global Healthcare Conference on May 13, 2026. Key leaders will discuss the company's innovative strategies and developments in biotechnology. A live webcast will be available for broader access.
May 04, 2026 Amgen Inc. Bolsters U.S. Manufacturing with $300 Million Investment Amgen Inc. has announced a $300 million investment to strengthen its U.S. manufacturing, particularly in Puerto Rico. This move is part of a broader $2 billion commitment to enhance production capacity and create jobs across various states.
May 01, 2026 Amgen Inc. Reports Strong Q1 2026 Results Amidst Macroeconomic Challenges Amgen Inc. reported a net income of $1.81 billion for Q1 2026, driven by a 4% increase in product sales and a strong cash position. Despite facing macroeconomic challenges, the company remains focused on innovation and operational efficiency.
April 30, 2026 Amgen Inc. Reports Strong Q1 Results Amidst Competitive Landscape Amgen Inc. reported a 6% revenue growth in Q1 2026, driven by strong product performance with 16 products achieving double-digit sales growth. The company's leadership remains optimistic about future growth amid competitive pressures.
April 24, 2026 Amgen Inc. to Report First Quarter 2026 Financial Results Amgen Inc. will release its Q1 2026 financial results on April 30, followed by a conference call led by CEO Robert A. Bradway. The event will be accessible via a live webcast, promoting transparency and engagement with investors.
April 22, 2026 Amgen Inc. Announces Retirement of David M. Reese Amgen Inc. has announced the retirement of Dr. David M. Reese, effective June 30, 2026, after a notable career in biotechnology. His leadership in 'convergent innovation' has shaped the company’s approach to research and development, and several key appointments are set to follow his departure to advance Amgen's mission.
April 06, 2026 Amgen Reports Positive Phase 3 Results for Subcutaneous TEPEZZA in Thyroid Eye Disease Amgen's Phase 3 trial of TEPEZZA delivered via subcutaneous injection shows a 77% response rate in treating Thyroid Eye Disease. The results indicate significant improvements in symptoms, enhancing treatment accessibility for patients.
March 28, 2026 Repatha® Shows Promise in Reducing Cardiovascular Risk for High-Risk Patients Amgen's Repatha® has demonstrated a significant 31% reduction in major cardiovascular events among high-risk patients in the VESALIUS-CV trial. These findings underscore the importance of early LDL-C lowering in preventing cardiovascular disease.
March 05, 2026 Amgen Inc.: Upcoming Presentation at the Leerink Partners 2026 Global Healthcare Conference Amgen Inc. will participate in the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026. The event will showcase executive insights on biotech innovations and feature a live webcast for broader access.
March 04, 2026 Amgen Declares Second Quarter 2026 Dividend: A Commitment to Shareholder Value Amgen Inc. has declared a quarterly dividend of $2.52 per share for Q2 2026, emphasizing its strong financial position and commitment to shareholders. The company continues to innovate in biotechnology while navigating market challenges.
February 24, 2026 Amgen Inc. to Present at the 46th Annual TD Cowen Health Care Conference Amgen Inc. will participate in the 46th Annual TD Cowen Health Care Conference, featuring key executives discussing the company's strategic direction and innovations. A live webcast will be available for those unable to attend in person.
February 13, 2026 Amgen to Showcase Innovations at Citi's Virtual Oncology Leadership Summit Amgen will present at the Citi Virtual Oncology Leadership Summit on February 18, 2026, showcasing its latest innovations in cancer treatment. The presentation will be accessible via a live webcast, reflecting Amgen's commitment to transparency and stakeholder engagement in oncology.
February 13, 2026 Amgen Inc. Reports Strong Performance in 2025 Annual Report Amgen Inc. has reported a remarkable 10% rise in sales for 2025, achieving $36.75 billion in revenue. The company highlights regulatory achievements and commitment to sustainability while addressing competitive challenges.
February 12, 2026 Amgen Inc. Secures European Commission Approval for UPLIZNA® in Treating Generalized Myasthenia Gravis Amgen's UPLIZNA® has received European Commission approval as an add-on therapy for adults with generalized myasthenia gravis, targeting specific patient populations. This significant milestone aims to enhance patient outcomes while reducing long-term steroid use, backed by compelling clinical trial data.
February 03, 2026 Amgen Inc. Reports Strong Financial Performance for Fourth Quarter and Full Year 2025 Amgen Inc. showcased impressive financial results for Q4 2025, with revenues hitting $9.9 billion, a 9% increase year-over-year. The company celebrated record sales for eighteen products, driving significant earnings growth and solid cash flow, positioning it well for 2026.
January 28, 2026 Amgen Inc. to Present 2025 Financial Results in Upcoming Webcast Amgen Inc. will present its 2025 financial results on February 3, 2026, during a live webcast. The event, featuring CEO Robert A. Bradway, aims to engage investors with insights into the company's performance and future strategies. The webcast will also be available for replay for 90 days.
January 07, 2026 Amgen Inc. Set to Make Waves at the 44th Annual J.P. Morgan Healthcare Conference Amgen Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Robert A. Bradway's presentation will be accessible via a live webcast. This event underlines Amgen's commitment to innovation in biotechnology and its role in advancing therapeutic solutions for patients.
January 06, 2026 Amgen Expands Oncology Pipeline with Dark Blue Therapeutics Acquisition Amgen Inc. has announced its acquisition of Dark Blue Therapeutics to strengthen its oncology pipeline, focusing on a novel therapy targeting acute myeloid leukemia. This strategic move is aimed at developing new treatment options for this aggressive cancer, leveraging promising preclinical data.
December 19, 2025 Amgen Inc. Partners with U.S. Government to Lower Medicine Costs for Patients Amgen Inc. has partnered with the U.S. government to reduce medication costs for patients, expanding its AmgenNow™ program to offer significant discounts on key drugs. The initiative reflects Amgen's commitment to innovation and affordable healthcare, backed by substantial investments in U.S. manufacturing.
December 11, 2025 Amgen Inc. Receives FDA Approval for UPLIZNA®: A New Hope for Patients with Generalized Myasthenia Gravis Amgen Inc. has received FDA approval for UPLIZNA®, a new treatment for generalized myasthenia gravis, promising improved patient outcomes with a novel mechanism. The drug offers a simplified dosing schedule and has shown significant clinical trial success.
December 09, 2025 Amgen Inc. Declares First Quarter Dividend for 2026 Amgen Inc. has declared a $2.52 per share dividend for the first quarter of 2026, reaffirming its dedication to shareholder value. This announcement reflects Amgen's strong financial performance and strategic growth initiatives in the biotechnology sector.
November 24, 2025 Amgen Inc. Set to Present at Citi's 2025 Global Healthcare Conference Amgen Inc. is set to present at the Citi's 2025 Global Healthcare Conference on December 3, featuring key executives. The event will be streamed live, highlighting Amgen's dedication to transparency and innovation in biotechnology.
November 24, 2025 Amgen Gears Up for the 8th Annual Evercore ISI HealthCONx Conference Amgen Inc. will present at the 8th annual Evercore ISI HealthCONx Conference on December 3, 2025. Key executives will discuss the company's strategic direction and innovations in biotechnology, which can be accessed via a live webcast.
November 19, 2025 Amgen Inc. Secures Full FDA Approval for Innovative Lung Cancer Therapy IMDELLTRA® Amgen Inc. has secured full FDA approval for IMDELLTRA, a therapy for extensive stage small cell lung cancer. Supported by the DeLLphi-304 study, it significantly improves survival rates over traditional chemotherapy. The NCCN has also recognized it as a preferred treatment option, paving the way for better patient outcomes.
November 08, 2025 Amgen's Repatha® Achieves Landmark Results in VESALIUS-CV Trial Amgen's VESALIUS-CV trial reveals that Repatha® significantly reduces cardiovascular event risks by 25% in high-risk adults. With notable improvements in lipid profiles and no new safety concerns, these findings underscore the drug’s importance in managing cardiovascular health.
November 05, 2025 Amgen Inc. Reports Strong Q3 2025 Results Amid Regulatory Changes and Market Challenges Amgen Inc. has reported strong Q3 2025 results, showing a 12% increase in revenue and significant net income growth. The company navigates regulatory challenges while expanding its product portfolio, including new approvals for Repatha and TEZSPIRE.
November 04, 2025 Amgen Inc Reports Robust Third Quarter 2025 Financial Results Amgen Inc achieved a 12% revenue increase in Q3 2025, totaling $9.6 billion, driven by strong product sales and commitment to innovation. The company reported substantial earnings growth despite some challenges, showcasing its robust pipeline and strategic investments.
October 31, 2025 Amgen Inc. Declares Fourth Quarter Dividend for 2025 Amgen has declared a $2.38 dividend per share for Q4 2025, reaffirming its commitment to shareholders amid strong operational performance. The dividend will be paid on December 12, 2025, reflecting Amgen's strategic growth and financial stability.
October 31, 2025 Amgen Inc. to Unveil Groundbreaking Repatha Data at AHA 2025 Amgen Inc. will present pivotal data from the VESALIUS-CV trial of Repatha at AHA 2025, highlighting its effectiveness in reducing cardiovascular risks. This trial marks a significant advancement in treatment options for high-risk patients, showcasing Amgen's commitment to innovative cardiovascular research.
October 29, 2025 Amgen Inc. Set to Release Q3 2025 Financial Results Amgen Inc. is set to disclose its Q3 2025 financial results on November 4, followed by a conference call featuring CEO Robert A. Bradway. The event promises insights into Amgen's performance and future strategies, attracting significant interest from investors.
October 22, 2025 Amgen Inc. Faces Investigation Over Fiduciary Duties: Halper Sadeh LLC Steps In Halper Sadeh LLC is investigating Amgen Inc. for potential breaches of fiduciary duties by its officers and directors, particularly affecting shareholders before July 29, 2020. The firm encourages affected shareholders to consider their rights and potential actions, which may include governance reforms and financial recovery. Engaging in this legal process could enhance corporate accountability and shareholder value.
October 17, 2025 Amgen Inc. Announces FDA Approval for TEZSPIRE® Treatment of Chronic Rhinosinusitis with Nasal Polyps Amgen Inc. and AstraZeneca announce FDA approval of TEZSPIRE® for chronic rhinosinusitis with nasal polyps, a groundbreaking treatment targeting TSLP. This biologic offers hope for patients with severe symptoms who have not responded to traditional therapies.
October 07, 2025 Amgen Launches AmgenNow: A Direct-to-Patient Program for Repatha Amgen has launched AmgenNow, a direct-to-patient program providing the cholesterol-lowering drug Repatha at a drastically reduced price of $239/month. This initiative aims to simplify access for patients, including those without insurance or facing high deductibles, while supporting the Trump Administration's drug cost reduction efforts.
October 02, 2025 Amgen's VESALIUS-CV Trial Achieves Landmark Success in Cardiovascular Prevention Amgen's VESALIUS-CV trial shows that Repatha® significantly reduces major cardiovascular events in high-risk patients without prior heart issues. This landmark study expands the treatment's application and showcases its safety, potentially saving millions of lives.
September 26, 2025 Amgen Inc. Announces Major $650 Million Manufacturing Expansion Amgen Inc. has announced a $650 million expansion of its U.S. manufacturing network, creating nearly 750 jobs and enhancing its biologics facility in Puerto Rico. This investment underscores the company's commitment to U.S. biomanufacturing and aims to strengthen the global supply chain and local economies.
September 08, 2025 Amgen and Kyowa Kirin Announce Promising Results from Rocatinlimab Phase 3 Study Amgen and Kyowa Kirin announced positive results from the Phase 3 ASCEND study on Rocatinlimab, a treatment for moderate to severe atopic dermatitis. The study highlights the drug's potential long-term efficacy and safety, promising new hope for affected patients.
September 04, 2025 Amgen Set to Present at Morgan Stanley Global Healthcare Conference Amgen will present at the Morgan Stanley Global Healthcare Conference on September 9, 2025, featuring insights from top executives. The event will be webcast for wider accessibility, highlighting Amgen's commitment to innovation and its significant market position.
September 02, 2025 Amgen Inc. Unveils Ambitious $600 Million Investment in New Science and Innovation Center Amgen Inc. announced a $600 million investment in a new science and innovation center in Thousand Oaks, California, aimed at advancing biotechnology research. This facility will foster collaboration among scientists, enhance operational capabilities, and is expected to create hundreds of jobs. The investment highlights Amgen's ongoing commitment to innovation and the U.S. economy.
August 29, 2025 Amgen Inc. Set to Present at the 2025 Wells Fargo Healthcare Conference Amgen Inc. will present at the 2025 Wells Fargo Healthcare Conference on September 3, 2025. Dr. Paul Burton will lead the session, sharing insights on the company's innovations and strategic direction. The presentation will be available via a live webcast and archived for 90 days.
August 25, 2025 Amgen Expands Repatha® Indication to Combat Cardiovascular Risks Amgen has received FDA approval to expand the use of Repatha® for adults at risk of major cardiovascular events due to high LDL cholesterol. This significant update allows broader access for patients needing effective cholesterol management.
August 21, 2025 Singzyme Triumphs in 2025 Amgen x NSG Golden Ticket Programme Singzyme has been awarded the 2025 Golden Ticket by Amgen and NSG BioLabs, recognizing its innovative PAL platform for antibody-drug conjugates. This award provides essential resources and mentorship to accelerate Singzyme's advancements in precision medicine, highlighting Singapore's growing biotech sector.
August 06, 2025 Amgen Inc. Reports Strong Q2 2025 Results Amidst Challenges Amgen Inc. demonstrated remarkable financial strength in Q2 2025, reporting a 91% increase in net income year-over-year. Despite facing macroeconomic challenges, the company's innovative pipeline and strategic investments position it for continued growth.
August 05, 2025 Amgen Reports Strong Financial Performance in Q2 2025 Amgen Inc. reported strong financial results for Q2 2025, achieving $9.2 billion in revenues and a 92% increase in GAAP EPS. The growth was driven by significant sales in multiple products and operational efficiencies, positioning the company for sustained success in the biotechnology sector.
August 01, 2025 Amgen Inc. Declares Third Quarter Dividend for 2025 Amgen Inc. has declared a $2.38 per share dividend for the third quarter of 2025, demonstrating its solid financial health and dedication to shareholders. The company continues to focus on innovation in biotechnology, aiming for growth despite industry challenges.
July 31, 2025 Amgen Inc. Prepares to Unveil Second Quarter Financial Results for 2025 Amgen Inc. will release its financial results for Q2 2025 on August 5, followed by a conference call with senior management. This event is crucial for investors seeking insights into the company's performance and strategic direction.
June 30, 2025 Amgen Inc. Announces Promising Phase 3 Results for Bemarituzumab in Gastric Cancer Treatment Amgen has reported promising Phase 3 results for bemarituzumab in treating gastric cancer, demonstrating improved overall survival in patients. The trial's success paves the way for targeted therapies in a field with significant unmet needs.
June 23, 2025 Amgen Inc. Reports Promising Results for MariTide in Phase 2 Obesity Study Amgen's Phase 2 study of MariTide shows impressive weight loss results, averaging 20% in non-diabetic individuals and 17% in those with Type 2 diabetes. The study highlights improved safety and tolerability, paving the way for the upcoming Phase 3 MARITIME program focused on chronic weight management.
June 18, 2025 Amgen Inc. Presents Promising Data on MariTide at ADA Scientific Sessions Amgen Inc. will present promising Phase 2 results for MariTide at the ADA Scientific Sessions 2025, highlighting its efficacy in treating obesity. The data show robust weight loss without plateau effects, as Amgen aims to revolutionize obesity care and engage with the medical community.
June 13, 2025 Amgen and Barry Sanders Spotlight Cholesterol Risks in New Documentary Amgen launches *The Making of a Heart Attack*, a documentary featuring Barry Sanders addressing the silent risks of high LDL cholesterol and urging proactive health management. With expert insights and personal stories, the film aims to raise awareness and reduce cardiovascular disease in the U.S.
June 05, 2025 Amgen Inc. Set to Showcase Innovations at Goldman Sachs Healthcare Conference Amgen Inc. will present at the Goldman Sachs Healthcare Conference on June 10, 2025, showcasing their innovative pipeline and strategic insights. Key executives will share financial and R&D developments, with a live webcast available for broader access.
June 02, 2025 Amgen Inc. Announces Groundbreaking Results for IMDELLTRA® in Small Cell Lung Cancer Amgen Inc. has announced that its treatment IMDELLTRA® significantly reduces death risk by 40% in small cell lung cancer patients, extending median survival by over five months. The Phase 3 DeLLphi-304 trial results highlight the treatment's potential to reshape SCLC management and improve patient outcomes.
May 30, 2025 Amgen Set to Present at Jefferies Global Healthcare Conference Amgen Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2025, showcasing key insights from its executives. The event will be webcast live, ensuring accessibility for all stakeholders.
May 16, 2025 Amgen to Present at the 2025 RBC Capital Markets Global Healthcare Conference Amgen Inc. will participate in the 2025 RBC Capital Markets Global Healthcare Conference on May 21, featuring insights from Kave Niksefat. The event will be available via live webcast, emphasizing Amgen's commitment to transparency in its innovative healthcare initiatives.
May 09, 2025 Amgen to Showcase Innovations at Bank of America Merrill Lynch Global Healthcare Conference Amgen Inc. will participate in the Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2025, showcasing its innovations in biotechnology. Key executives will present insights, and a live webcast will be available for broader accessibility. Amgen continues to lead in healthcare advancements and stakeholder engagement.
May 02, 2025 Amgen Inc. Reports Strong Financial Performance in 2025 Q1 Amgen Inc. has reported a remarkable financial turnaround in Q1 2025, with a net income of $1.73 billion and a 9.4% increase in total revenue. The company is navigating macroeconomic challenges while expanding its product pipeline and addressing unmet medical needs.
May 01, 2025 Amgen Reports Strong First Quarter 2025 Financial Results Amgen reported impressive Q1 2025 results, with revenues at $8.1 billion and a 9% year-over-year increase. The company's robust product sales and positive earnings metrics underscore its strong market position and future growth potential.
April 28, 2025 Amgen Set to Release First Quarter Financial Results on May 1, 2025 Amgen Inc. will announce its first quarter financial results for 2025 on May 1, followed by a conference call featuring CEO Robert A. Bradway. The webcast will be accessible for all stakeholders, emphasizing Amgen's commitment to transparency and innovation.
April 25, 2025 Amgen Inc. Announces Major Manufacturing Expansion in Ohio Amgen Inc. has unveiled a $900 million investment in expanding its Ohio manufacturing facility, creating 350 new jobs. This move emphasizes Amgen's commitment to U.S. manufacturing and will enhance its biomanufacturing capabilities while benefiting the local economy.
April 11, 2025 Amgen Inc. Announces Significant Breakthrough in Small Cell Lung Cancer Treatment with IMDELLTRA® Amgen Inc. announced promising Phase 3 trial results for IMDELLTRA®, an innovative treatment for small cell lung cancer, showing improved survival rates. The trial demonstrated its potential as a new standard of care, targeting DLL3 to activate T cells against SCLC cells. Amgen's commitment to advancing treatment options highlights the urgent need for effective therapies in this aggressive cancer.
April 03, 2025 Amgen Inc. Achieves Historic FDA Approval for UPLIZNA® in IgG4-Related Disease Amgen Inc. has achieved FDA approval for UPLIZNA® as the first treatment for IgG4-related disease. This groundbreaking approval follows significant trial results showing a 87% reduction in disease flare-ups and a commitment to improving patient care.
March 13, 2025 Amgen Inc. Announces Positive Phase 3 Results for UPLIZNA® in Generalized Myasthenia Gravis Amgen's Phase 3 MINT trial reveals UPLIZNA's significant efficacy and safety in treating generalized myasthenia gravis, with potential for a new standard of care. The trial's findings indicate substantial symptom improvement and a novel corticosteroid tapering approach, promising hope for affected patients.
March 08, 2025 Amgen and Kyowa Kirin Announce Promising Results from Rocatinlimab Phase 3 IGNITE Study Amgen and Kyowa Kirin announced significant findings from their Phase 3 IGNITE study on Rocatinlimab, showing improved outcomes for adults with moderate to severe atopic dermatitis. The study met its primary endpoint, indicating Rocatinlimab as a promising new treatment option for patients unresponsive to existing therapies.
March 04, 2025 Amgen Inc. Declares Second Quarter Dividend for 2025 Amgen Inc. has declared a dividend of $2.38 per share for the second quarter of 2025, to be paid on June 6. This decision highlights the company's commitment to shareholder returns and its ongoing innovation in biotechnology.
March 01, 2025 Amgen and AstraZeneca Unveil Promising Results for TEZSPIRE® in Chronic Rhinosinusitis with Nasal Polyps Amgen and AstraZeneca announced positive Phase 3 results for TEZSPIRE® in treating chronic rhinosinusitis with nasal polyps, showing significant reductions in symptom severity and surgical needs. The trial results indicate a potential breakthrough for patients, with TEZSPIRE reducing the need for surgery by 98% and corticosteroid use by 88%.
February 28, 2025 Amgen Inc. Set to Present at the 45th Annual TD Cowen Health Care Conference Amgen Inc. will present at the 45th Annual TD Cowen Health Care Conference on March 5, 2025, with Executive VP Jay Bradner leading a fireside chat. The event highlights Amgen's commitment to biotechnology and innovative patient care solutions.
February 14, 2025 Amgen Inc. Reports Strong Financial Performance in 2024 Annual Report Amgen Inc. reported strong financial results for 2024, with a revenue increase of 18.5% to $33.42 billion driven by robust product sales. Despite challenges, the company focuses on innovation and strategic acquisitions to enhance its therapeutic offerings.
February 14, 2025 Amgen Inc. Set to Showcase Innovations at Citi's 2025 Virtual Oncology Leadership Summit Amgen Inc. will present its latest oncology innovations at Citi's 2025 Virtual Oncology Leadership Summit on February 19, 2025. The live webcast will feature insights from Senior VP Jean-Charles Soria and highlight Amgen's commitment to enhancing patient outcomes through innovative therapies.
February 07, 2025 SWOT Analysis of Amgen Inc. in 2025 This SWOT analysis of Amgen Inc. in 2025 highlights its strong product portfolio and market leadership, alongside challenges like legal issues and competition. It also identifies opportunities for growth in emerging markets and innovation.
February 07, 2025 Amgen Inc. Set to Present at Oppenheimer Healthcare Life Sciences Conference Amgen Inc. will present at the Oppenheimer Healthcare Life Sciences Conference on February 12, 2025. The event, featuring senior VP Narimon Honarpour, will be live-streamed and archived for later viewing, highlighting Amgen's innovative role in biotechnology.
October 31, 2024 Amgen Inc. Reports Strong Q3 2024 Financial Performance Amidst Pipeline Progress Amgen Inc. reported impressive Q3 2024 results, achieving $8.4 billion in product sales, a 24% increase year-over-year. The company also experienced a 64% rise in net income, reflecting effective cost management and strong product performance across its portfolio. Despite facing economic challenges, Amgen's growth trajectory remains promising.
August 07, 2024 Amgen Inc. Reports Strong Q2 2024 Results Amid Pipeline Advancements Amgen Inc. reported a robust 20% revenue growth in Q2 2024, attributed to strong product sales and successful pipeline advancements. The company is focused on innovation and managing expenses while preparing for future growth.
May 03, 2024 Amgen Inc. Reports Q1 2024 Financial Results: A Mixed Bag Amidst Ongoing Innovations Amgen Inc. reported a 22% increase in Q1 2024 revenues, driven by strong product sales; however, net income fell to a loss of $113 million. The company continues to invest heavily in R&D and plans to launch a Phase 3 obesity program, aiming for long-term growth despite short-term financial challenges.
